Document:

Filed by Automated Filing Services Inc. (604) 609-0244 - Med-Tech Solutions Inc. - Exhibit 10.1

 EXCLUSIVE LICENSE AGREEMENT

 This Exclusive License Agreement (the “Agreement”) is dated as
  of the 29th day of October, 2004

 BETWEEN:

	 	MDMI TECHNOLOGIES INC., a corporation
        incorporated under the Canada Business Corporations Act having an address
        at Suite 110-12051 Horseshoe Way, Richmond, British Columbia, Canada V7A
        4V2 
	 
	 	 	 
	 	(the “Licensor”) 
	 

OF THE FIRST PART

AND:

	 	MED-TECH SOLUTIONS, INC.,
        a Nevada corporation having an address at 2200-1177 West Hastings Street,
        Vancouver, British Columbia, Canada V6E 2K3 
	 
	 	 	 
	 	 (the “Licensee”) 	 

	A. 	The Licensor has developed a unique medical pessary device for the treatment
      of urinary incontinence (the “Apparatus”); 
	 	 
	B. 	 The Licensee desires to secure the license, right and permission to manufacture,
      market, distribute and sell the Apparatus; and 
	 	 
	C.	 The Licensor is willing to license the Apparatus to the Licensee for
      such development and use, upon the terms and subject to the conditions set
      forth in this Agreement. 

OF THE SECOND PART

 WHEREAS:

NOW THEREFORE THIS AGREEMENT WITNESSES that in consideration of the
  mutual covenants and agreements contained herein, the parties hereto agree as
  follows:

	1. 	DEFINITIONS 

In this Agreement, the following words and phrases shall have the following
  meanings: 

“Apparatus” has the meaning ascribed to it in the recitals
  to this Agreement; 

“Exclusive License” has the meaning ascribed to it in Section
  2.1 of this Agreement; 

 “Gross Profits” means the gross sales of
  the Technology or Products realized by the Licensee, less costs of goods sold
  of the Technology or Products and shipping, marketing and related costs attributable
  to sales of the Technology or Products, each as determined in accordance with
  generally accepted accounting principles (for greater certainty, no sales made
  by sub-licensees shall be included in the calculation of Gross Profits); 

 -2-

 “Improvement” means any modification or
  variant of the Technology, whether patentable or not, which, if manufactured,
  used, or sold, would fall within the scope of the Technology; 

 “Intellectual Property” means all copyrights,
  patent rights, trade secret rights, trade names, trademark rights, process information,
  technical information, designs, drawings, inventions and all other intellectual
  and industrial property rights of any sort related to or associated with the
  Technology; 

 “Know-how” means all know-how, knowledge,
  expertise, inventions, works of authorship, prototypes, technology, information,
  know-how, materials and tools relating thereto or to the design, development,
  manufacture, use and commercial application of the Technology; 

 “License Fee” has the meaning ascribed
  to it in Section 2.2 of this Agreement; 

“Products” means commercial goods or products
  incorporating the Technology; 

“Royalty” has the meaning ascribed to it
  in Section 3.1 of this Agreement; 

 “Technology” means any apparatus incorporating
  any or all of the architecture, know-how, engineering data and design of the
  Gynecone medical pessary device developed by the Licensor for the treatment
  of urinary incontinence, Improvements related thereto, and all related Trademarks,
  patents, patent applications, copyrights and trade secrets; and 

 “Trademarks” means the trademarks described
  in Schedule “A” to this Agreement.

	2.	GRANT OF EXCLUSIVE LICENSE 
	 	 
	2.1	 The Licensor grants to the Licensee
        the exclusive worldwide right and license to enjoy, commercialize and
        exploit the Technology and to manufacture, use and sell throughout the
        world, Products embodying the Technology (the “Exclusive License”).
      

	 	

	2.2 	 In consideration of the grant of the
        Exclusive License, the Licensee agrees to: 

	 	
	

	 	(a)
	 pay to the Licensor a license fee of CDN$10,000,
        within 10 days following the date of execution of this Agreement (the
        “License Fee”); and 

	 	
	

	 	(b)
	 pay the royalty set out in Article 3. 

	2.3 	The Exclusive License will be for a term of 50 years
        (the “Initial Term”) from the date this Agreement is executed,
        unless sooner terminated in accordance with the provisions of this Agreement.
      

	 	

	2.4 	 The Licensee shall have the option (the “Option”)
        to renew the Agreement for an additional period of 50 years. The Option
        shall be exercised by the Licensee's delivery to the Licensor, in person
        or by mail, on or before expiry of the Initial Term: (i) written notice
        of Licensee's election to renew the term of this Agreement; and (ii) an
        additional payment of CDN$10,000. 

 -3-

	3. 	ROYALTY 

	 	

	3.1 	 The Licensee shall pay to the Licensor
        a royalty (the “Royalty”) on the sale of the Technology or
        Products by the Licensee equal to 5% of Gross Profits. 

	 	

	3.2 	 The Royalty shall be payable on a quarterly
        basis within 52 days of the end of the Licensee’s fiscal quarter
        provided that the royalties payable with respect to the last quarter of
        each fiscal year will be payable within 107 days of the end of the Licensee’s
        fiscal year. 

	 	

	4. 	 RIGHT TO SUB-LICENSE
        

	 	

	4.1	 The Licensee shall have the right during
        the continuance of this Agreement to enter into agreements with other
        persons, firms or corporations, giving and granting to them or any of
        them the right to manufacture, use and sell Products embodying the Technology
        on such terms as the Licensee shall deem proper, except that in no case
        shall such terms, covenants and conditions impose a greater obligation
        on the Licensor than is provided by this Agreement. 

	 	

	4.2 	 The Licensee shall, prior to entering
        into any sub-license agreement, advise the Licensor of its intention to
        enter into the sub-license agreement and shall immediately after entering
        into any sub-license agreement provide a copy of the agreement to the
        Licensor. 

	 	

	5. 	 TITLE TO INTELLECTUAL PROPERTY
        / IMPROVEMENTS 

	 	

	5.1	 The Technology and trademarks included
        in the Technology shall remain the property of the Licensor subject to
        the Exclusive License granted by this Agreement. The Licensor shall, upon
        demand, execute and deliver to the Licensee such documents as may be deemed
        necessary by counsel for the Licensee for filing in appropriate government
        offices to evidence the granting of the Exclusive License. 

	 	

	5.2	 In the event the Licensee shall make
        any Improvements said Improvements and any applications and patents therefor
        shall likewise come under this Agreement and be subject to all the terms
        and provisions thereof. 

	 	

	6. 	 RIGHT OF FIRST REFUSAL
      

	 	

	6.1 	 The Licensor shall not transfer, sell,
        convey or assign the Technology or any component of it otherwise than
        in accordance with this Article. 

	 	

	6.2	 Should the Licensor intend to dispose
        of all or any portion of the Technology or its interest in it, the Licensor
        shall first give notice in writing to the Licensee of such intention together
        with the terms and conditions on which the Licensor intends to dispose
        of the Technology or its interest in it. 

	 	

	6.3	 If the Licensor receives any offer to
        dispose of all or any portion of the Technology or its interest in it,
        which it intends to accept, it shall not accept the same unless it has
        first offered to sell such interest to the Licensee on the same terms
        and conditions as in the offer received and the same has not been accepted
        by the Licensee. 

	 	

	6.4	 Any communication of an intention to
        sell pursuant to sections 6.2 and 6.3 (the "Offer") shall be in writing
        and shall: 

	 	

	 	(a)
	 set out in reasonable detail all of the terms and
        conditions of any intended sale; 

 -4-

	 	(b)
	 if it is made pursuant to section 6.3, include a
        photocopy of the Offer; and 

	 	
	

	 	(c)
	 if it is made pursuant to section 6.3, clearly identify
        the offering party and include such information as is known by the Licensor
        about such offering party; 

	 	
	

	 	and such communication will
        be deemed to constitute an Offer by the Licensor to the Licensee to sell
        the Licensor's interest to the Licensee on the terms and conditions set
        out in such Offer.

	 	

	6.5 	 Any Offer made as contemplated
        in section 6.4 shall be open for acceptance by the Licensee for a period
        of 30 days from the date of receipt of the Offer by the Licensee. 

	 	

	6.6 	 If the Licensee accepts
        the Offer within the period provided for in section 6.5, such acceptance
        shall constitute a binding agreement of purchase and sale between the
        Licensor and the Licensee, for the Interest on the terms and conditions
        set out in such Offer. 

	 	

	6.7	 If the Licensee does not
        accept the Offer within the period provided for in section 6.5, the Licensor
        may complete a sale and purchase of its Interest or a portion thereof
        on terms and conditions no less favorable to the Licensor than those set
        out in the Offer and, in the case of an Offer under section 6.3, only
        to the party making the original offer to the Licensor and in any event
        such sale and purchase shall be completed within nine months from the
        expiration of the right of the Licensee to accept such Offer or the Licensor
        must again comply with the provisions of this Article. 

	 	

	6.8 	 If the Licensee does accept
        the Offer within the period provided for in section 6.5 but fails to close
        the transaction contemplated thereby within 90 days following receipt
        of such Offer, the Licensor may complete a sale and purchase of its Interest
        or a portion thereof on any terms and conditions but in any event such
        sale and purchase shall be completed within nine months from the expiration
        of the right of the Licensee to accept such Offer or the Licensor must
        again comply with the provisions of this Article. 

	 	

	6.9	 While any Offer is outstanding
        no other Offer may be made until the first mentioned Offer is disposed
        of and any sale resulting therefrom completed or abandoned in accordance
        with the provisions of this Article. 

	 	

	7. 	TECHNICAL ASSISTANCE
        

	 	

	7.1	 The Licensor shall, at
        the Licensee’s request and expense, provide technical assistance
        to the Licensee within fifteen (15) days of a request by the Licensee
        to provide such assistance. 

	 	

	8.	 AUDIT
        

	 	

	8.1	 The Licensee shall keep
        and maintain during the currency of this Agreement such full and accurate
        records (including books of account) as are necessary to determine the
        amounts payable hereunder and shall permit a member of the American Institute
        of Public Accountants designated by the Licensor during normal business
        hours and upon reasonable notice to have full access to such records,
        to audit them, and to make copies of them solely for the purpose of verifying
        the accuracy thereof. The Licensor shall bear all costs of such examination
        unless such examination reveals a material misstatement or mispayment
        of the amount owing by the Licensee to the Licensor of 5% or more, in
        which event the Licensee shall bear all costs of such examination, and
        the Licensee agrees to promptly reimburse Licensor for such costs. 

 -5-

	 	If any such inspection reveals a shortfall in the
        royalties payable to the Licensor hereunder then the Licensee shall forthwith
        pay the full amount of such shortfall, plus interest as herein provided,
        to Licensor. 

	 	

	8.2	 For each of the Licensee’s fiscal years occurring
        wholly or partly during term of this Agreement, the Licensee shall within
        six months after the end of each such fiscal year, deliver to the Licensor
        a copy of the Licensee’s financial statements for such fiscal year.
      

	 	

	9. 	 INFRINGEMENT OF THIRD PARTY PATENTS OR TRADEMARKS
        

	 	

	9.1	 If any complaint alleging infringement or violation
        of any Trademark or other proprietary rights is made against the Licensor
        or its customers, licensees or sub-licensees in respect of the manufacture,
        use or sale of Products in any country, then the following procedure shall
        be adopted. The Licensee shall promptly upon receipt of any such complaint
        notify the Licensor of same, and shall throughout the pendency of such
        complaint keep the Licensor fully informed of the actions and positions
        taken by the complainant and taken and proposed to be taken by the Licensee.
        The Licensor may elect to participate formally in any litigation involving
        the complaint, to the extent that the court permits, but any additional
        expenses generated by such formal participation shall be borne entirely
        by the Licensor (subject to the possibility of recovery of some or all
        of such additional expenses from the complainant). 

	 	

	10. 	 INFRINGEMENT OF TRADEMARKS 

	 	

	10.1	 The Licensee shall keep a diligent watch in order
        to detect any products which infringe, or possibly infringe the Trademarks.
        Upon detection of any such infringement, or possible infringement, the
        Licensee shall take appropriate legal action to restrain such infringement
        and/or recover damages in respect thereof unless the Licensee is advised
        by its legal counsel that the infringement, in the opinion of counsel,
        is immaterial. The Licensor will, at no cost to the Licensee, assist the
        Licensee in such action by testifying in any legal proceedings, signing
        all necessary papers, and rendering any other assistance (except financial
        assistance) which may, in the opinion of the Licensee or its counsel,
        reasonably be required to prosecute such action to a successful conclusion.
        If the Licensee is successful in obtaining any award of damages as a result
        of such legal action, the Licensee shall be entitled to retain 95% of
        the proceeds from such action and the Licensor shall be entitled to retain
        5% of the proceeds. If the Licensee does not undertake legal action to
        restrain such infringement and/or recover damages in respect thereof,
        then the Licensor may undertake such action at the Licensor’s expense
        and be entitled to retain the full amount of any proceeds from such legal
        action. 

	 	

	11.	 DEFAULT 

	 	

	11.1	 If the Licensee is in default of any material obligation
        under this Agreement, then the Licensor may give notice of default (a
        “Notice of Licensee Default”) to the Licensee. Upon receipt
        of a Notice of Licensee Default and subject to the Licensee’s right
        to arbitrate a dispute as to a default, The Licensee will have a period
        in which to remedy the default (a “Licensee Remedy Period”).
        The Licensee Remedy Period will equal thirty (30) days if the default
        relates to non-payment of the License Fee or Royalty. The Licensee Remedy
        Period will equal sixty (60) days in any other case. 

	 	

	11.2 	 If the Licensee disputes that it is in default,
        it may give a notice to arbitrate to the Licensor (a “Notice to
        Arbitrate”). A Notice to Arbitrate must be given within the applicable
        Licensee Remedy Period. If the Licensee delivers a Notice to Arbitrate,
        then the dispute will be arbitrated in accordance with the arbitration
        provisions of this Agreement and the Licensee Remedy Period will be 

 -6-

	 	suspended until such time as the arbitrator reaches
        a decision. If the arbitrator determines that the Licensee is not in default
        of its obligations under this Agreement, then the Licensee will be deemed
        not to be in default of its obligations under this Agreement. If the arbitrator
        determines that the Licensee is in default of its obligations under this
        Agreement, then the Licensee Remedy Period will be deemed to re-commence
        on the date of the decision of the arbitrator and the Licensee will have
        either thirty (30) or sixty (60) days, as applicable, to remedy the default.
      

	 	

	11.3	 If the Licensee fails to remedy a default within
        the applicable Licensee Remedy Period, then the Exclusive License will
        terminate. 

	 	

	11.4	 If the Licensor is in default of any material obligation
        under this Agreement, then the Licensee may give notice of default (a
        “Notice of Licensor’s Default”) to the Licensor. Upon
        receipt of a Notice of Licensor’s Default and subject to the Licensor’s
        right to arbitrate a dispute as to a default, the Licensor will have a
        period of sixty (60) days in which to remedy the default (an “Licensor’s
        Remedy Period”).

	 	

	11.5	 If the Licensor disputes that it is in default,
        the Licensor may give a notice to arbitrate to the Licensee (a “Notice
        to Arbitrate”). A Notice to Arbitrate must be given within the applicable
        Licensor’s Remedy Period. If the Licensor delivers a Notice to Arbitrate,
        then the dispute will be arbitrated in accordance with the arbitration
        provisions of this Agreement and the Licensor’s Remedy Period will
        be suspended until such time as the arbitrator reaches a decision. If
        the arbitrator determines that the Licensor is not in default of its obligations
        under this Agreement, then the Licensor will be deemed not to be in default
        of their obligations under this Agreement. If the arbitrator determines
        that the Licensor is in default of its obligations under this Agreement,
        then the Licensor’s Remedy Period will be deemed to commence on
        the date of the decision of the arbitrator and the Licensor will have
        thirty (30) to remedy the default. 

	 	

	11.6	 If the Licensor fails to remedy a default within
        the applicable Licensor’s Remedy Period, then the obligation of
        the Licensee to pay the Royalty will be suspended until such time as the
        default is remedied by the Licensor, provided that the Licensee will be
        entitled to deduct any damages arising from the default from any future
        payment of the Royalty. 

	 	

	12. 	 ARBITRATION OF DISPUTES 

	 	

	12.1	 Arbitration of any dispute arising under this Agreement
        will be held in the city of Vancouver, British Columbia under the commercial
        rules and procedures of the Commercial Arbitration Act (British
        Columbia). Any matter presented for arbitration will be settled by arbitration
        proceedings conducted by a single arbitrator. The arbitrator will be appointed
        by agreement between the parties or, in default of agreement, such arbitrator
        will be appointed by a Judge of the Supreme Court of British Columbia
        sitting in Vancouver, upon the application of any of the said parties
        and a Judge of the Supreme Court of British Columbia sitting in Vancouver
        will be entitled to act as such arbitrator, if he so desires. The decision
        of the arbitrator as to any matter in dispute under this Agreement will
        be binding and conclusive upon the parties. The decision of the arbitrator
        will be rendered in writing and will include the basis for the decision.
        Judgment upon any award rendered by the arbitrators may be entered in
        any court having jurisdiction. The non-prevailing party to an arbitration
        will pay its own expenses, the fees of each arbitrator, including without
        limitation, attorneys’ fees and costs, reasonably incurred by the
        prevailing party to the arbitration.

 -7-

	13. 	INTEREST ON OVERDUE PAYMENTS
        

	 	

	13.1	 Except as otherwise specified herein,
        interest shall accrue on all overdue payments hereunder from the due date
        for such payment until actual payment, such interest to be computed at
        an effective annual interest rate of twelve percent (12%) per annum. 

	 	

	14.	 INDEMNIFICATION

	 	

	14.1	 The Licensee agrees to indemnify, defend
        and hold harmless Licensor (including its officers, directors, employees
        and agents) from and against any/all claims, damages, liabilities, settlement
        costs and expenses (including reasonable legal fees) arising directly
        or indirectly from or relating to the Licensee’s breach of any material
        term or condition of this Agreement. 

	 	

	14.2 	 In no event shall either Party to this
        Agreement be liable to the other (including its officers, directors, employees
        and/or agents) for any indirect, special, incidental or consequential
        damages whatsoever, including, without limitation, damages in the nature
        of lost profits or business interruption, whether arising in contract
        (including fundamental breach), tort (including negligence) or otherwise,
        even if the other Party was advised of the possibility of such damages,
        or whether such damages were foreseeable. 

	 	

	15.	 EQUAL PARTICIPATION IN DRAFTING
        

	 	

	15.1	 The parties have equally participated
        in the drafting of the within Agreement, each having had the opportunity
        to be independently represented by counsel. The Licensor acknowledges
        that O’Neill Law Group PLLC have acted solely for the Licensee in
        connection with the preparation, negotiation and execution of this Agreement
        and the Licensor has been advised to obtain the advice of independent
        legal counsel in entering into this Agreement. 

	 	

	16. 	 REPRESENTATIONS AND WARRANTIES
        OF THE LICENSOR 

	 	

	16.1 	 The Licensor represents and warrants
        to the Licensee that: 

	 	 
	 	(a) 	The execution and delivery of this Agreement by the
        Licensor has been duly authorized. The person executing this Agreement
        on behalf of the Licensor has full and proper authorization to execute
        same, and this Agreement is the valid and binding agreement of the Licensor
        and is enforceable against the Licensor in accordance with its terms.
      

	 	 	

	 	(b)	 The Licensor warrants that the Trademarks are genuine
        and valid, that it has sole title to them, and full right, authority and
        power to enter into this Agreement, and that it shall indemnify and save
        harmless the Licensee against any and all rights and contracts that may
        be held or claimed by others. 

	 	 	

	17.	REPRESENTATIONS AND WARRANTIES OF THE LICENSEE
    
	 	 
	17.1	 The Licensee represents and warrants to the
      Licensor that: 
	 	 
	 	(a)	 The execution and delivery of this
        Agreement by the Licensee has been duly authorized. The person executing
        this Agreement on behalf of the Licensee has full and proper authorization
        to execute same, and this Agreement is the valid and 

 -8-

	 	 	binding agreement of the Licensee and is enforceable against the Licensee
      in accordance with its terms.

	18. 	MISCELLANEOUS PROVISIONS 

	 	

	18.1 	 No cancellation, modification, amendment, deletion,
        addition or other change in this Agreement or any provision hereof, or
        waiver of any right or remedy hereby provided, shall be effective for
        any purpose unless specifically set forth in writing, signed by the party
        to be bound thereby. No waiver of any right or remedy in respect of any
        occurrence or event on one occasion shall be deemed a waiver of such right
        or remedy in respect of such occurrence or event on any other occasion.
      

	 	

	18.2 	 This Agreement shall be construed in accordance
        with, and governed by, the laws of the Province of British Columbia, and
        the federal laws of Canada applicable therein, without giving effect to
        any choice or conflict of law provision or rule (whether of the Province
        of British Columbia or any other jurisdiction) that would cause the application
        of the laws of any jurisdiction other than the laws of the Province of
        British Columbia and the federal laws of Canada applicable therein, and
        the parties irrevocably submit to the non-exclusive jurisdiction of the
        Supreme Court of British Columbia. 

	 	

	18.3 	 The headings are inserted solely for convenience
        of reference and shall not be deemed to restrict or modify the meaning
        of the Articles to which they pertain. 

	 	

	18.4 	 This Agreement constitutes the entire agreement
        between the parties with respect to all matters herein contained, and
        its execution has not been induced by, nor do any of the parties hereto
        rely upon or regard as material, any representations or writings whatsoever
        not incorporated herein and made a part hereof. This Agreement shall not
        be amended, altered or qualified except by an instrument in writing, signed
        by all parties hereto and any amendments, alterations or qualifications
        hereof shall not be binding upon or affect the rights of any party who
        has not given its consent in writing. 

	 	

	18.5 	 The division of this Agreement into articles and
        sections is for convenience of reference only and shall not affect the
        interpretation or construction of this Agreement. 

	 	

	18.6 	 In the event that any of the covenants herein contained
        shall be held unenforceable or declared invalid for any reason whatsoever,
        such unenforceability or invalidity shall not affect the enforceability
        or validity of the remaining provisions of this Agreement and such unenforceable
        or invalid portion shall be severable from the remainder of this Agreement.
      

	 	

	18.7 	In the event of an inability or failure by any party
        by reason of any fire, explosion, war, riot, strike, walk-out, labour
        controversy, flood, shortage of water, power, labour transportation facilities
        or necessary materials or supplies, default or power failure of carriers,
        breakdown in or the loss of production or anticipated production from
        plant or equipment, act of God or public enemy, any law, act or order
        of any court, board, government or other authority of competent jurisdiction,
        or any other direct cause (whether or not of the same character as the
        foregoing) beyond the reasonable control of the party, then the party
        shall not be liable to the other party and will not be deemed to be in
        default during the period and to the extent of such inability or failure.

	 	

	18.8 	 Any notice required or permitted to be given hereunder
        shall be in writing and shall be effectively given if: 

 -9-

	 	(a)	 Delivered personally;
	 	 	 
	 	(b) 	 Sent by prepaid courier service or mail;
	 	 	 
	 	(c) 	 Sent prepaid by telecopiers, fax, telex or other similar means of electronic
      communication; or 
	 	 	 
	 	(d)	 Addressed to the relevant Party at the address/fax number shown for that
      Party at the beginning of this Agreement. 

Any notice so given shall be deemed conclusively to have been
  given and received when so personally delivered or, if sent by telex, fax, telecopier
  or other electronic communication, on the first business day thereafter, or
  if sent by mail on the third business day thereafter. Any party may change any
  particulars of its address/fax number for notice by notice to the others in
  the manner above described.

	18.9	 Time shall be of the essence of this Agreement.
      

	 	

	18.10	 The parties agree to sign such other instruments,
        cause such meetings to be held, resolutions passed and by-laws enacted,
        exercise their vote and influence, do and perform and cause to be done
        and performed such further and other acts and things as may be necessary
        or desirable in order to give full effect to this Agreement. 

	 	

	18.11 	This Agreement shall enure to the benefit of and
        be binding upon the parties hereto and their respective successors and
        permitted assigns. 

	 	

	18.12	 The relationship between the Licensor and the Licensee
        is, and during the term of this Agreement shall be that of independent
        contractors. No party shall be deemed a legal representative or agent
        of the other party for any purpose and shall have no right or authority
        to assume or create in writing or otherwise, any obligation of any kind,
        express or implied, with respect to any commitments, in the name of the
        other party or on behalf of the other party, unless given with the express
        written authority of such party. Furthermore, the relationship among the
        Licensor and the Licensee hereunder shall not constitute a joint venture,
        general partnership or similar arrangement. 

 -10-

	18.13 	This agreement may be executed in one or more counterparts,
        each of which so executed shall constitute an original and all of which
        together shall constitute one and the same agreement. 

IN WITNESS WHEREOF the parties hereto have executed this Agreement and
  as of the date and year first above written. 

	 MED-TECH SOLUTIONS, INC.  	 	 MDMI TECHNOLOGIES INC.  
	 by its authorized signatory  	 	 by its authorized signatory:  
	 	 	 
	 /s/ Mark A. McLeary  	 	 /s/ Terry Kehoe  
	 	 	 
	 Signature of Authorized Signatory  	 	 Signature of Authorized Signatory  
	 	 	 
	 Mark A. McLeary  	 	 Terry Kehoe  
	 	 	 
	 Name of Authorized Signatory  	 	 Name of Authorized Signatory  
	 	 	 
	 President  	 	 Vice President and COO  
	 	 	 
	 Position of Authorized Signatory  	 	 Position of Authorized Signatory  

SCHEDULE A 

to that Exclusive License Agreement dated as of October 29, 2004 

 TRADEMARKS AND TRADENAMES

	 	1.	 GYNECONEFiled by Automated Filing Services Inc. (604) 609-0244 - Med-Tech Solutions Inc. - Exhibit 10.2

 MANUFACTURING AGREEMENT

 This Agreement dated as of the 25 day of January, 2005 

 BETWEEN:

	 	Med-Tech Solutions Inc.,
        a company duly incorporated pursuant to the laws of the State of Nevada
        and having its office at Suite 2200 – 1177 West Hastings Street,
        Vancouver, B.C., V6E 2K3 
	 
	 	 	 
	 	 (the "Company") 	 

AND:

	 	MDMI TECHNOLOGIES INC. (FORMERLY
        M.D.M.I. MANUFACTURING CANADA LTD.), a company duly
        incorporated pursuant to the laws of Canada and having its office at 110-12051
        Horseshoe Way Richmond, BC, V7A 4C8 
	 
	 	 	 
	 	(the "Manufacturer") 	 

WHEREAS:

	A.	 The Manufacturer has agreed to manufacture a certain
        urinary incontinence apparatus described in Schedule “A” attached
        hereto on behalf of the Company, for use in the women’s health care
        industry, according to the quality standards of the Company; and the Company
        has agreed to purchase such products from the Manufacturer, on the terms
        of this Agreement. 

	 	

	B. 	 The Company originally acquired the rights to the
        aforesaid urinary incontinence apparatus pursuant to an exclusive license
        agreement dated October 29, 2004 (the “Technology Acquisition Agreement”).
      

	 	

	 THEREFORE in consideration of the mutual covenants
      in this Agreement and other good and valuable consideration, receipt of
      which is acknowledged, the parties hereto agree as follows: 
	 	

	1.0	DEFINITIONS 

	 	

	 	In this Agreement: 

	 	

	1.1	 "Documentation" means any technical or user
        manuals or documentation related to or necessary for the use of the Products,
        in English and in various foreign-language versions; 

	 	

	1.2 	 "MDMI Document Control System" means the
        document control system implemented by the Manufacturer. 

	 	

	1.3	"Products" means the products described in
        Schedule "A" attached to and forming part of this Agreement, which
        pursuant to this Agreement will be manufactured by the Manufacturer on
        behalf of the Company. 

	 	

	1.4 	 "Specifications" means the Product manufacturing
        specifications originally given to the Company by the Manufacturer pursuant
        to the Technology Acquisition Agreement, and referred to in Schedule "A",
        as amended from time to time by the Company. 

 - 2 -

	1.5 	The following schedules
        are attached to and form part of this Agreement: 

	 	
	

	 	(1)
	 Schedule "A" Products and Specifications

	 	
	

	 	(2)
	 Schedule "B" Price List 

	 	
	

	2.0	

      PRODUCTS AND PRICE 

	 	
	

	2.1	Products: The Manufacturer
        will manufacture the Products in Canada exclusively for the Company, according
        to the Specifications, during the Term of this Agreement. The Company
        will purchase the Products from the Manufacturer for the price and in
        the manner set out in this Agreement. The Manufacturer will sell the Products
        only to the Company and to no other person or entity. 

	 	
	

	2.2	Price: The price
        of the Products will be the price set out in Schedule "B" to this
        Agreement (the "Price"), as amended pursuant to this Agreement.
        All prices and amounts set out in this Agreement are expressed in United
        States dollars. 

	 	
	

	2.3	First 180 Days: For
        the first 180 days of production pursuant to this Agreement (the "180-Day
        Period"), the parties will monitor the costs of manufacturing the
        Products. Within 2 weeks of the conclusion of the 180-Day Period, the
        parties may renegotiate the Price. In the event of a failure to agree
        on a renegotiated Price, either:

	 	
	

	 	(1)
	 the Price set out in Schedule "B"
        will continue; or 

	 	
	

	 	(2)
	 the Agreement may be terminated by
        mutual consent. 

	 	
	

	2.4 	Price Changes: After
        the 180-Day Period, Manufacturer will not change the Price unless: 

	 	
	

	 	(1)
	 The Manufacturer demonstrates that
        its costs to manufacture the Products have changed proportionately to
        the proposed change;

	 	
	

	 	(2)
	 The Company and the Manufacturer agree
        to evenly split cost savings due to part or process improvements; 

	 	
	

	 	(3)
	 The Manufacturer provides a written
        request for such a proposed change more than 90 days prior to the proposed
        effective date of such change; 

	 	
	

	 	(4) 
	 The Company approves such change in
        writing; 

	 	
	

	 	(5) 
	 A new Schedule "B" reflecting the price
        change is issued for this Agreement.

	 	 	 
	2.5 	New Products: The
        Company will provide advance written notice to the Manufacturer of any
        products which are to be added to this Agreement. By consent of both parties,
        all relevant Schedules will be amended or if necessary new Schedules will
        be added in respect of specifications, price, materials and equipment,
        etc. related to any new products. The terms of this Agreement will apply
        to such new products, which will be deemed to fall under the definition
        of "Products".

	 	
	

	3.0	 SPECIFICATIONS &
        QUALITY CONTROL 

	 	
	

	3.1	 Obligations of the Manufacturer: The
      Manufacturer will:

 - 3 -

	 	(1) 	manufacture and test the Products to
        the uniform, high quality standards established by the Company, which
        meet or exceed all the Specifications;

	 	 	

	 	(2)	  manufacture the Products in quantities
        sufficient to meet the demand for the Product; 

	 	 	

	 	(3)	  maintain by itself, or through its
        agents, an adequate stock of the materials and parts required to manufacture
        the Products in accordance with this Agreement;

	 	 	

	 	(4) 	 employ sufficient competent and experienced
        personnel, who are skilled and trained in the manufacture of the Products;

	 	 	

	 	(5)	 provide appropriate manufacturing facilities
        in Canada for the manufacture of the Products; 

	 	 	

	 	(6)	  provide standard hand tools and equipment
        listed in Schedule "B";

	 	 	

	 	(7)	  maintain a quality system in accordance
        with ISO13485 and provide the Company with documentation to support
        quality system status;

	 	 	

	 	(8)	  notify the Company immediately in writing
        in the event: 

	 	 	

	 	 	(1)
	 the Manufacturer is unable to maintain quality system
        certification in accordance with ISO Standards, or, 

	 	 	
	

	 	 	(2) 
	of any non-conformities specifically relating to
        the Specifications or Products. 

	 	 	 
	 	 	(9)	 if the Manufacturer fails to meet the obligations
        set out above then the Company may holdback 15% of all unpaid invoices
        until a satisfactory resolution is obtained. 

	 	 	 
	3.2	Samples: The Manufacturer
        will provide the Company with sample units of the Products at time of
        its first shipment of the Products. If the Company requests, the Manufacturer
        will provide the Company with further "control" samples of the Products
        at any time. 

	 	
	

	3.3	 Changes to Specifications:
        The Manufacturer may not vary or change the Specifications without prior
        written approval from the Company. The Company may vary, change, update
        or amend the Specifications from time to time by advance written notice
        to the Manufacturer. Changes to Price resulting from changes to Specifications
        must be mutually agreed upon in writing.

	 	
	

	3.4	 MDMI Document Control
        System: The Manufacturer will document all changes to the Specifications
        within the MDMI Document Control System. 

	 	
	

	3.5	 Records: The Manufacturer
        will maintain all related manufacturing and employment records for a period
        not less than 7 years following production of the Product. At any time
        during business hours, the Company may conduct a comprehensive audit of
        the Manufacturer's manufacturing, packaging and storage facilities, as
        well as reviewing standard operating procedures, manufacturing and employment
        records, and any other relevant information pertaining to the Products.
        The Company may appoint representatives from an independent organization
        to conduct these audits on its behalf. The Manufacturer will provide appropriate
        records to any authority (including any Notified Body or Competent Authority
        of the European Community) responsible for ensuring compliance with ISO
        standard certification. The Manufacturer will, at the Company's request,
        provide any quality control testing documentation. The Company will maintain
        all distribution and post-marketing monitoring records.

 - 4 -

	3.6	Quality Control: The Manufacturer
        will ensure that all quality control measures and applicable federal and
        provincial legislation and regulations are complied with, and will conduct
        ongoing quality assurance testing. 

	 	

	4.0	 PACKAGING 

	 	

	4.1	Packaging: The Manufacturer will
        pack the Products according to the Specifications, or as specified on
        the Purchase Order. If the Company develops unique packaging and/or delivery
        systems for the Products, the Manufacturer will not use such unique packaging
        and/or delivery systems with any other person, firm or entity in any country
        where the Company sells Products during the term of this Agreement and
        for twelve (12) months after the termination of this Agreement. For greater
        certainty all packaging materials shall be supplied by the Manufacturer
        and shall be included in the price described in Schedule “B”.
      

	 	

	4.2	 Packing Slip: Each shipment of
        Product will contain a packing slip complete with a lot number. 

	 	

	4.3	 Certificate of Conformance: Each
        shipment of Product will contain a certificate of conformance which certifies
        that every Product in the shipment meets the Specifications. 

	 	

	5.0 	 REPRESENTATIONS AND WARRANTIES
      

	 	

	5.1	 Manufacturer's Representations and
        Warranties: Manufacturer warrants, represents and covenants to the
        Company that: 

	 	

	 	(1)
	Authority: The Manufacturer has the necessary
        corporate authority and capacity to enter into this Agreement; 

	 	
	

	 	(2)
	 Ability: The Manufacturer has the necessary
        skill, ability and expertise to perform its obligations under this Agreement;

	 	
	

	 	(3)
	 Defects: The Manufacturer warrants that each
        shipment of Product will be manufactured and tested to the Specifications
        and will be free of defects. The Manufacturer warrants that if defects
        in the Products which prevent substantial conformance to the Specifications
        occur during the term of this Agreement then, provided that the Company
        provides prompt notice and full and complete disclosure of such defects
        to the Manufacturer; the Manufacturer will use its best efforts to either
        correct such errors or replace the defective Products within 60 days following
        receipt of notice from the Company of such defects, failing which any
        monies paid by the Company in respect of the purchase of such Products
        will be refunded. 

	 	

	6.0	 TRADEMARKS 

	 	

	6.1	Ownership: The Manufacturer acknowledges
        and agrees that Med-Tech Solutions, Inc. ("the Company) owns the trademarks,
        trade names and service marks “Gynecone”, as amended from
        time to time in the sole discretion of the Company, subject in any event
        to the terms of the Technology Acquisition Agreement..

	 	

	6.2	 Restriction: The Manufacturer
        will not use any trademark or trade name belonging to the Company on any
        Products or Packaging or otherwise, other than as set out in this Agreement.
        The Manufacturer will not sell any Products bearing any of the Trademarks
        to any person or entity other than the Company. The Manufacturer will
        not manufacture any Products bearing any of the Trademarks for any person
        or entity other than the Company. The Manufacturer will not use the trade
        name of “Gynecone” without prior written consent from the
        Company. 

 - 5 -

	6.3	Competing Products: During the
        term of this Agreement and for a period of twelve months thereafter the
        Manufacturer will neither manufacture, distribute or sell any other products
        which are similar to or competitive to the Products. 

	 	

	7.0 	 INTELLECTUAL PROPERTY, CONFIDENTIALITY
        & USE RESTRICTIONS 

	 	

	7.1	 Technology: The Manufacturer
        acknowledges and agrees that, except for the limited manufacturing rights
        granted in this Agreement, the Company exclusively owns and retains any
        and all right, title and interest to the Specifications, including but
        not limited to all intellectual property, trade secrets, and know-how
        whether or not subject to patent protection or copyright, associated with
        the Specification, design and manufacture of the Products (the "Technology"),
        subject in any event to the Terms of the Technology Acquisition Agreement.
      

	 	

	7.2	 Patents: In the event the Company
        applies for a patent or other intellectual property protection in respect
        of the Technology or Products, the Manufacturer will continue to have
        the right to manufacture the Products as provided herein. 

	 	

	7.3	 Confidential Information: The
        Manufacturer agrees that the Company has a proprietary interest in any
        information provided to the Manufacturer by the Company in connection
        with this Agreement whether in written or oral form, which is: 

	 	

	 	(1)
	 a trade secret, confidential or proprietary information
        relating to the Products or the Technology, 

	 	
	

	 	(2)
	 not publicly known, and

	 	
	

	 	(3)
	 communicated with an expectation of confidentiality
        or marked as confidential or proprietary information (the "Confidential
        Information"). 

	 	
	

	7.4 	Exceptions: The Manufacturer
        will not be liable for a disclosure of the Confidential Information if
        the information so disclosed: 

	 	
	

	 	(1)
	 was in the public domain at the time of disclosure
        without breach of this Agreement; or

	 	
	

	 	(2)
	 was known to or contained in the records of the
        Manufacturer from a source other than the Company at the time of disclosure
        by the Company to the Manufacturer and can be so demonstrated; or

	 	
	

	 	(3) 
	was independently developed and is so demonstrated
        promptly upon receipt of the documentation and technology by the Manufacturer;
        or

	 	
	

	 	(4) 
	becomes known to the Manufacturer from a source other
        than the Company without breach of this Agreement by the Manufacturer
        and can be so demonstrated; or 

	 	
	

	 	(5)
	 was disclosed pursuant to court order. 

	 	
	

	 	The exclusions in clauses
        (2), (3) and (4) above will not apply to Confidential Information which
        relates to the Technology originally acquired by the Company pursuant
        to the Technology Acquisition Agreement. 

	 	

	7.5	 Restrictions: The
        Manufacturer will disclose the Confidential Information only to those
        of its agents and employees to whom it is necessary in order to properly
        carry out their duties as limited by the terms and conditions of this
        Agreement. Both during and after the term of this Agreement, all disclosures
        by the Manufacturer to its agents and employees will be held in strict
        confidence by such agents and employees. During and after the term of
        this Agreement, the Manufacturer, its agents and employees will not use
        the Confidential Information for any purpose other than in connection
        with the Manufacturer's manufacture of the Product pursuant to this Agreement.
        The Manufacturer will, at its expense, return the Confidential Information
        to the Company as soon as practicable after the termination or expiration
        of this Agreement. All such Confidential Information will remain the exclusive
        property of the Company during the term of this 

 - 6 -

	 	Agreement and thereafter. This Section will also
        apply to any consultants or subcontractors that the Manufacturer may engage
        in connection with its obligations under this Agreement. 

	 	

	7.6 	 Non-Disclosure by Manufacturer: The Manufacturer
        will not disclose any Confidential Information regarding any aspect of
        Technology, or its manufacturing processes, or any aspect of its business
        dealings with the Company to any person firm or entity, without the prior
        written permission of the Company, including but not limited to the Specifications
        and any other information related to the manufacturing, packaging, marketing,
        or selling of the Products. 

	 	

	7.7	 Non-Disclosure by Med-Tech Solutions, Inc.:
        Except as required by applicable securities laws, the Company will not
        disclose any information regarding any aspect of its business dealings
        with the Manufacturer to any person, firm, or entity without the prior
        written permission of the Manufacturer. 

	 	

	7.8	 Restriction: The Manufacturer will not disassemble
        or decompile the Products or any part thereof for any purpose other than
        the purpose of manufacturing the Products pursuant to this Agreement.
        The Manufacturer will not customize, modify or have customized or modified
        any Products unless it obtains the prior written consent of the Company.
      

	 	

	8.0	 ORDERS AND DELIVERY 

	 	

	8.1	 Purchase Order: Each order by the Company
        will be made with a Purchase Order to specify quantity, price, and delivery
        dates, as well as any other requirements. The Manufacturer is required
        to return signed acknowledgement of the Purchase Order to the Company.
      

	 	

	8.2	Order Fulfullment: The Manufacturer will use
        its reasonable efforts to fill all orders placed by the Company for the
        Products in accordance with the delivery dates requested by the Company.
      

	 	

	8.3	 Risk: Title to and risk of loss of any shipment
        of the Products remains with the Manufacturer until such shipment is received
        by the Company. 

	 	

	8.4	Returned Stock: The Manufacturer will accept
        returned Products from the Company with respect to any stock that is non-conforming
        to Specifications, or is received damaged, mislabeled, mispackaged or
        in otherwise unusable condition, at 100% of current acquisition cost plus
        any applicable handling and shipping fees. 

	 	

	8.5	 Payment: The Company will pay the Manufacturer
        for the Products within 15 days (Net 15) of receipt of invoice, with billing
        to occur on the 15th and 30th of each month for
        shipments delivered within each period.

	 	

	9.0	 TERM 

	 	

	9.1	Term: This Agreement commences on the date
        first written on page one and continues for an indefinite period thereafter
        (the "Term") until terminated according to Section 2.3 above or
        Section 10.0 below. This Agreement may be renewed by mutual consent of
        the parties. 

	 	

	10.0	 TERMINATION 

	 	

	10.1	 Termination: Either the Company or the Manufacturer
        may terminate this Agreement by giving three months written notice to
        the other party including a defined date of termination, or immediately
        by mutual written agreement. 

	 	

	10.2	 Rights over Inventory: If the Company terminates
        this Agreement pursuant to Paragraph 10.1, then: 

- 7 -

	 	(1)
	 the Company will purchase all of the Manufacturer's
        inventory of any Finished Products that have been manufactured
        pursuant to a purchase order from the Company; 

	 	
	

	 	(2)
	 the Company will purchase at cost any materials,
        Component Parts or Raw Goods, less the cost of materials supplied
        by the Company, on hand up to (but not exceeding) the amount of such materials
        required to manufacture that number of Products which were manufactured
        in the three months preceding the date of termination; and h Products
        to the Company. 

	 	
	

	 	(3)
	 provided the Manufacturer has any finished inventory
        of Products in excess of the Products referred to in 10.2(1), then the
        Manufacturer will without charge deliver suc

	 	
	

	10.3	 Events of Default:
        Notwithstanding the above, the Company may terminate this agreement immediately
        and without liability if: 

	 	
	

	 	(1)
	 the Manufacturer declares bankruptcy or becomes
        insolvent or enters into receivership; 

	 	
	

	 	(2)
	 any Product of the Manufacturer fails to meet the
        Specifications, which failure is not remedied or corrected within 15 days
        of receiving written notice of such failure; or 

	 	
	

	 	(3)
	 the Manufacturer does not remedy a breach of this
        Agreement (other than any failure of any Product to meet the Specifications)
        within 30 days of receiving written notice of such breach. 

	 	
	

	10.4	 Rights on Termination:
        On termination of this Agreement, the Manufacturer will, without charge
        and at the option of the Company, destroy or deliver to the Company all
        finished inventory of Packaging and packaging material bearing the Company
        trademarks, in excess of three (3) months regular inventory. On termination
        of this Agreement, the Manufacturer will cease using the Technology and
        the Trademarks for any purpose. 

	 	

	11.0	 INSURANCE AND INDEMNITY
      

	 	

	11.1	 Insurance: The Manufacturer
        will obtain comprehensive general liability insurance, including product
        liability coverage with respect to the Products, in the amount of not
        less than one million dollars ($1,000,000.00) per occurrence,
        with the Company as a named insured. 

	 	

	11.2	 Insurance Information:
        The Manufacturer will provide the Company with current information with
        respect to its insurance coverage on an ongoing basis, and will forward
        any new information to the Company within ten (10) working days of receipt
        of such new information. 

	 	

	11.3 	 Legal Requirements:
        The Manufacturer will ensure compliance with all legal requirements, whether
        imposed by statute, regulation, or otherwise, related to the manufacturing
        of the Products, and will be solely responsible for the consequences of
        any failure to meet such legal requirements. 

	 	

	11.4	 Indemnity: The Manufacturer
        will indemnify and hold harmless the Company and its respective directors,
        officers, employees and agents from and against: 

	 	

	 	(1)
	 any and all liabilities, whether accrued,
        absolute, contingent or otherwise, with respect to any failure on the
        part of the Manufacturer under paragraph 11.3; 

	 	
	

	 	(2) 
	any and all damages or deficiencies
        resulting from any misrepresentation, breach of warranty or non-fulfillment
        of any covenant on the part of the Manufacturer under this Agreement;
        and 

 - 8 -

	 	(3)	 any and all actions, suits, proceedings, demands,
        assessments, judgments, costs, including product recall costs and legal
        costs on a full- indemnity basis, and other expenses incidental to the
        foregoing. 

	 	 	 
	11.5 	 Indemnity: the Company will indemnify
      and hold harmless the Manufacturer and its respective directors, officers,
      employees and agents from and against: 
	 	 	 
	 	(1)	 any and all damages, actions, suits, proceedings,
        demands, assessments, judgments, costs, including product recall costs
        and legal costs on a full- indemnity basis, and other expenses suffered
        by the Manufacturer arising out of an error or defect in the Specifications
        provided to the Manufacturer by the Company, but only if and to the extent
        that such Specifications were amended by the Company after being initially
        acquired from the Manufacturer pursuant to the Technology Acquisition
        Agreement, and for greater certainty the Manufacturer will provide the
        same indemnity to the Company for any damages, actions, et cetera, arising
        out of an error or defect in the Specifications which were originally
        provided to the Company by the Manufacturer.

	 	 	

	 	(2) 	 a claim by a third party that its intellectual property
        rights are infringed by one of the Products, including by the manufacture,
        use, or sale of one of the Products, but only to the extent that the claim
        arises by reason of changes made to the Specifications after being initially
        acquired from the Manufacturer pursuant to the Technology Acquisition
        Agreement 

	 	 	 
	12.0	GENERAL 
	 	 	 
	12.1	 It is specifically understood
        and agreed that the Manufacturer, in entering into and carrying out its
        duties under this Agreement, has the status of an independent contractor.
        Under no circumstances shall Manufacturer, or its agents or employees,
        be deemed to be, or represent themselves as, the agents or employees of
        the Company. Additionally, it is specifically agreed that this Agreement
        shall not create any partnership, joint venture or similar relationship
        between the parties hereto, and no representations to the contrary shall
        be made by either party. Neither of the parties hereto, nor their agents
        or employees shall have any authority to act for or on behalf of, or to
        bind the other party in any fashion, and no representations to the contrary
        shall be made by either party hereto or their agents or employees. 

	 	
	

	12.2	 Neither the Company nor
        the Manufacturer will be responsible for delays or defaults in respect
        of this Agreement that result from war (whether or not declared), riot,
        terrorism, earthquake, fire, flood, or other acts of God, or acts of the
        Queen or Her enemies, but the party claiming relief under this paragraph
        will notify the other party within 48 hours when such a delay or default
        is anticipated. If any delay in performance due to an event of force majeure
        continues for a period of twelve months (12) from the date the said event
        occurs or commences, this Agreement shall automatically terminate without
        further obligation of any kind of either party to the other. 

	 	
	

	12.3	 The Manufacturer will not,
        without the prior written consent of the Company, assign any of its rights
        under this Agreement, which consent may be unreasonably withheld. 

	 	
	

	12.4	 This Agreement may be executed
        in any number of counterparts, or by facsimile, each of which when delivered
        will be deemed to be an original, for all purposes and will constitute
        one and the same instrument, binding on the parties, notwithstanding that
        all the parties are not signatories of the same counterpart or facsimile.
      

	 	
	

	12.5	 This Agreement enures to
        the benefit of and is binding upon the parties and their respective successors
        and permitted assigns. 

 - 9 -

	12.6 	Each of the parties hereby covenants
        and agrees to execute any further and other documents and instruments
        and to do any further and other things that may be necessary to implement
        and carry out the intent of this Agreement. 

	 	

	12.7 	 This Agreement will be governed by and
        construed in accordance with the law of the Province of British Columbia,
        without regard to its conflicts of laws principles, which law will be
        deemed to be the proper law of this Agreement, and the Courts of British
        Columbia will have exclusive jurisdiction to entertain and determine all
        claims for injunctive relief at law or in equity, arising out of or in
        any way connected with the construction, breach, or alleged, threatened,
        or anticipated breach of this Agreement.

	 	

	12.8 	 The captions appearing in this Agreement
        are for reference and as a matter of convenience only and in no way affect
        the meaning of the provisions of this Agreement. 

	 	

	12.9	 No consent or waiver, express or implied,
        of any party in respect of any breach or default by the other party of
        its obligations under this Agreement will constitute a consent or waiver
        in respect of any other breach or default of such obligations or any other
        obligation of that party. 

	 	

	12.10	 All notices or other communications
        provided for in this Agreement will be deemed to have been given, delivered
        or made if they are in writing and either mailed by certified mail, return
        receipt requested, faxed with answer-back confirmation, or actually delivered
        to the applicable party to the addresses below. All notices, requests,
        demands, directions and other communications will be deemed to have been
        received: when faxed, on transmission; when mailed, on the 7th calendar
        day after being mailed, addressed as described above. 

	 	

	 	 If to MDMI: . 
	The Manager Business Development 

        MDMI Technologies Inc

        110-12051 Horseshoe Way 

        Richmond, BC, Canada V7A 4C8 

        FAX: (604) 275-7970 

        TEL: (604) 275-7944 

	 	
	

	 	 If to the Company: 
	Med-Tech Solutions, Inc. 

        2200 – 1177 West Hastings Street 

        Vancouver, B.C, V6E 2K3 

        TEL: (604) 688-7526 

        FAX: (604) 647-0631 

	 	

	12.11	 This Agreement will be read with such
        changes in number and gender as the context or the reference may require.
      

	 	

	12.12	 If any provision in this Agreement is
        invalid, illegal or unenforceable in any respect in any jurisdiction,
        the validity, legality and enforceability of such provision will not be
        affected or impaired in any other jurisdiction and the validity, legality
        and enforceability of the remaining provisions in this Agreement will
        not in any way be affected or impaired thereby, unless in either case
        as a result of such determination this Agreement would fail in its essential
        purpose. 

	 	

	12.13 	 All disputes between the parties arising
        in connection with this Agreement shall be finally settled by arbitration,
        but subject to the right of parties to seek injunctive relief pursuant
        to paragraph 12.7. The arbitration shall be held in a mutually agreeable
        location, and shall be 

 - 10 -

	 	conducted in accordance with the British Columbia
        International Commercial Arbitration Center Rules of the International
        Chamber of Commerce. Judgment upon the award rendered may be entered in
        any court having jurisdiction or application may be made to such court
        for a judicial acceptance of the award and an order of enforcement, as
        the case may be. In any arbitration proceeding, the arbitrator(s) shall
        have the right and authority to award to the prevailing party the costs,
        including attorney fees, incurred by such party in connection with such
        arbitration. 

	 	

	12.14 	 Time will be of the essence of this Agreement. 

	 	

	12.15	 This Agreement, including all Schedules, constitutes
        the entire agreement between the parties and supersedes all previous communications,
        representations, understandings and agreements whether verbal or written
        between the parties with respect to the subject matter of this Agreement.
        This Agreement may only be amended by a document signed by both parties.
      

	 	

	 	 IN WITNESS WHEREOF the parties have hereunto set
        their hands and seals as of the day and year first above written. 

MED-TECH SOLUTIONS, INC.  by its authorized signatory(ies): 

	 /s/ Mark A. McLeary 

      Authorized Signatory  
	 Name:   Mark A. McLeary     
	 

	
	 
	 

	
	 

	
	
MDMI TECHNOLOGIES INC. by its 
	
	
authorized signatory(ies): 
	
	 

	
	 

	
	 /s/ Terry Kehoe  

      Authorized Signatory  
	 Name:   Terry Kehoe

 - 11 -

 SCHEDULE "A"

	 	PRODUCTS & SPECIFICATIONS 
	 	 
	 	 Silicone Elastomer MED-6010 (Body) 

      Silicone Elastomer MED-6010 (Coating) 

      Silicone Elastomer TUFEL 2 (Tab) 

      Primer CF1-135 

      Silicone Adhesive MED-1011

      Silicone ink marking R-1008-6 

      Colorings - Liquitex Acrylic Color 

      Fly Line Scientific Anglers 

      Magnetic Weight Bell or Ball Sinker 

      Tungsten Powder Weight Option

      Heat Shrink Tube o3/32" 

      Stainless Steel Wire o.032" Type 304 

 - 12 -

 SCHEDULE "B"

	 	PRICING & QUOTATION

The price of each urinary incontinence apparatus, including materials, labour
  and packaging, shall be US$10.00 per unit.

For greater certainty the price shall be the same for all differing sizes of the apparatus.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00077-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00077-of-00352.parquet"}]]